Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213645 | 1.00 | CES2 (0.52) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL14088061 | 1.00 | CES2 (0.52) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL1318224 | 1.00 | CES2 (0.52) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL9667227 | 0.84 | CES2 (0.50) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL2812852 | 0.83 | UGT2B7 (0.56) | HDAC4MEN1KMT2AUGT2B7 | |
| SCHEMBL9331659 | 0.83 | UGT2B7 (0.56) | HDAC4MEN1KMT2AUGT2B7 | |
| SCHEMBL9331663 | 0.83 | UGT2B7 (0.56) | HDAC4MEN1KMT2AUGT2B7 | |
| SCHEMBL9334664 | 0.83 | UGT2B7 (0.56) | HDAC4MEN1KMT2AUGT2B7 | |
| SCHEMBL15050759 | 0.83 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL15050756 | 0.83 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | claimed |
| US-20230023066-A1 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2023-01-26 | — | — | US | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-4868344-A | OPTICALLY PURE HALOALCOHOLS | ALDRICH-BORANES, INC. (US) | 1989-09-19 | — | — | US | claimed |
| EP-4676481-A1 | COMBINATION OF BETA-2-ADRENERGIC RECEPTOR AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR USE IN TREATING HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4665321-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND METFORMIN FOR USE IN TREATING OBESITY AND REDUCING BODY FAT | Atrogi AB (SE) | 2025-12-24 | — | — | EP | disclosed |
| EP-4651867-A1 | BETA 2-ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OR PREVENTION OF MUSCLE WASTING | Atrogi AB (SE) | 2025-11-26 | — | — | EP | disclosed |
| CN-119977739-A | Method for preparing nitrile compound by oxidizing alcohol compound to break C-C bond | 中国科学院大连化学物理研究所 | 2025-05-13 | — | — | CN | disclosed |
| US-20240343695-A1 | Lysophosphatidic Acid Receptor 1 Antagonists as Migrastatics for Cancer | LAKEHEAD UNIVERSITY (CA) | 2024-10-17 | — | — | US | disclosed |
| EP-4444707-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240317709-A1 | Lysophosphatidic Acid Receptor Antagonists for Breast Cancer Treatment | UNIV LAKEHEAD (CA) | 2024-09-26 | — | — | US | disclosed |
| WO-2024184408-A1 | COMBINATION OF BETA-2-ADRENERGIC RECEPTOR AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-09-12 | — | — | WO | disclosed |
| WO-2003099763-A1 | N-ACYLAMINOBENZENE DERVATIVES AS SELECTIVE MONOAMINE OXIDASE B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-04 | — | — | WO | disclosed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
| WO-2002072549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, SNCA | CES2 2482/4885CES1 2450/4885HDAC4 3257/4885 |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | CES2 1432/4885CES1 996/4885HDAC4 1378/4885 |
| US-20240317709-A1 | Lysophosphatidic Acid Receptor Antagonists for Breast Cancer Treatment | LPAR3, LPAR1, LPAR4 | CES2 3623/4885CES1 1022/4885HDAC4 856/4885 |
| US-20230023066-A1 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | CES2 3697/4885CES1 4421/4885HDAC4 3224/4885 |
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | CES2 293/4885CES1 244/4885HDAC4 1650/4885 |
| US-20240343695-A1 | Lysophosphatidic Acid Receptor 1 Antagonists as Migrastatics for Cancer | LPAR1, LPAR3, LPAR4 | CES2 3304/4885CES1 835/4885HDAC4 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.